Vepured
E. coli verotoxoid vaccine (inactivated recombinant)
Table of contents
Overview
This is a summary of the European public assessment report (EPAR) for Vepured.It explains how the Agency assessed this veterinary medicine to recommend its authorisation in the European Union (EU) and its conditions of use. It is not intended to provide practical advice on how to use Vepured.
For practical information about using Vepured, animal owners or keepers should read the package leaflet or contact their veterinarian or pharmacist.
Authorisation details
Product details | |
---|---|
Name |
Vepured
|
Agency product number |
EMEA/V/C/004364
|
Active substance |
recombinant Verotoxin 2e of E. coli
|
International non-proprietary name (INN) or common name |
E. coli verotoxoid vaccine (inactivated recombinant)
|
Species |
Pigs
|
Anatomical therapeutic chemical veterinary (ATCvet) codes |
QI09AB02
|
Publication details | |
---|---|
Marketing-authorisation holder |
Laboratorios Hipra, S.A.
|
Revision |
3
|
Date of issue of marketing authorisation valid throughout the European Union |
17/08/2017
|
Contact address |
Avda. La Selva, 135 |
Product information
05/11/2021 Vepured - EMEA/V/C/004364 - IB-0005
This medicine’s product information is available in all official EU languages.
Select ‘available languages’ to access the language you need.
Product information documents contain:
- summary of product characteristics (annex I);
- manufacturing authorisation holder responsible for batch release (annex IIA);
- conditions of the marketing authorisation (annex IIB);
- labelling (annex IIIA);
- package leaflet (annex IIIB).
You can find product information documents for centrally authorised human medicines on this website. For centrally authorised veterinary medicines authorised or updated from February 2022, see the Veterinary Medicines Information website.
Pharmacotherapeutic group
-
Immunologicals for suidae
-
Inactivated bacterial vaccines (including mycoplasma, toxoid and chlamydia) escherichia + clostridium
Therapeutic indication
Active immunisation of piglets from 2 days of age to prevent mortality and reduce clinical signs of oedema disease (caused by verotoxin 2e produced by E. coli) and to reduce the loss of daily weight gain during the finishing period in the face of infections with verotoxin 2e producing E. coli until slaughter from 164 days of age.